Clinical trials: Patients With Prostate Cancer
Prostate Cancer
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
Patients are being asked to take place in this research study because they have advanced prostate cancer that has gotten worse after other treatments.
- Trial name
- NCT01845792
- Testing
- Cabazitaxel with Abiraterone Acetate, Cabazitaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Colorado, Denver
Benign Prostatic Hyperplasia
Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)
Purpose: To evaluate the efficacy of prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH) and refractory lower urinary tract symptoms (LUTS) in decreasing the volume of the prostate gland.
- Trial name
- NCT02167919
- Testing
- Microspheres
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Prostate Cancer
GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
RATIONALE: GTI-2040 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00087165
- Testing
- GTI-2040, docetaxel, prednisone
- Where
- 5 sites in Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Hypereosinophilic Syndrome, Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the…
- Conditions
- Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma
- Trial name
- NCT00171912
- Testing
- imatinib mesylate
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer
Hyperthermia therapy may kill prostate cancer cells by heating them to several degrees above body temperature. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003045
- Testing
- Hyperthermia, XRT
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer Patients Treated by Radiotherapy
SpaceOAR Post-Market Registry Study
Recently, concerns have been raised by regulators that there is little data about the long-term safety of rectal hydrogel spacers for use in conjunction with radiotherapy treatment for prostate cancer.
- Trial name
- OASIS (NCT07300631)
- Testing
- SpaceOAR / SpaceOAR Vue hydrogel system
- Where
- 8 sites in France, United Kingdom
- Volunteers
- 320 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer.
- Trial name
- NCT00004211
- Testing
- PSA RNA-pulsed dendritic cell vaccine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Duke University
Prostatic Neoplasms
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
- Trial name
- NCT00313781
- Testing
- CP-751,871, docetaxel, prednisone
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 204 people
- Sponsor
- Pfizer
Prostate Cancer, Adenocarcinoma of the Prostate
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer
- Trial name
- NCT00879619
- Testing
- sunitinib malate, docetaxel, prednisone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- John P. Fruehauf
Colorectal Cancer, Lung Cancer
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer
- Trial name
- NCT00054977
- Testing
- GM-CT-01, 5-fluorouracil
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Galectin Therapeutics Inc.
Adenocarcinoma of the Prostate, Stage I Prostate Cancer
Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate
Green tea extract contains ingredients that may prevent or slow the growth of prostate cancer. This phase I trial is studying how well green tea extract works in treating patients with prostate cancer undergoing surgery to remove…
- Conditions
- Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- NCT00459407
- Testing
- defined green tea catechin extract, immunohistochemistry staining method, immunoenzyme technique
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Androgen Deprivation Therapy, Prostate Cancer
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer…
- Conditions
- Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic
- Trial name
- NCT05327465
- Testing
- Aerobic and resistance exercise, Usual Care
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)
The purpose of this real-world study of electronic medical records is to look back to compare the time to next treatment after initial treatment with enzalutamide or darolutamide in addition to androgen deprivation therapy (ADT).
- Trial name
- NCT07779590
- Testing
- darolutamide plus androgen deprivation therapy, Enzalutamide plus androgen deprivation therapy
- Where
- United States
- Volunteers
- 4,700 people
- Sponsor
- Pfizer
Prostate Cancer
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens.
- Trial name
- NCT00030654
- Testing
- bicalutamide, docetaxel, doxorubicin hydrochloride
- Where
- 78 sites in United States, Australia and 2 more
- Volunteers
- 21 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer Metastatic
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
Primary Objective: To compare the radiographic progression-free survival (rPFS) (using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for tumor lesions and Prostate Cancer Working Group 2 (PCWG2) criteria for bone scan…
- Trial name
- CARD (NCT02485691)
- Testing
- cabazitaxel XRP6258, enzalutamide, abiraterone acetate
- Where
- 65 sites in Austria, Belgium and 11 more
- Volunteers
- 255 people
- Sponsor
- Sanofi
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Prostatic Neoplasms
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
This trial represents an attempt to offer second line immunotherapy plus chemotherapy to patients who have failed prior taxane base therapy.
- Trial name
- NCT00447473
- Testing
- GM-CSF, Ketoconazole, Mitoxantrone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Cancer, Prostate Cancer
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone.
- Trial name
- NCT00634582
- Testing
- paricalcitol, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Cost-utility of Focal HIFU vs Prostatectomy
Medico-Economic Randomized Trial comparing Focal HIFU Treatment to Radical Prostatectomy in Patients with Favorable Intermediate Risk Prostate Cancer
- Trial name
- EMERHIT (NCT05710861)
- Testing
- F-HIFU, Radical Prostatectomy
- Where
- 20 sites in France, Guadeloupe
- Volunteers
- 346 people
- Sponsor
- University Hospital, Bordeaux
Prostate Cancer
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Interstitial brachytherapy uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00063882
- Testing
- Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation Therapy
- Where
- 170 sites in United States, Canada
- Volunteers
- 588 people
- Sponsor
- Radiation Therapy Oncology Group